Tyra Biosciences, Inc.
TYRA
$10.04
-$0.05-0.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -86.48M | -83.74M | -80.88M | -75.45M | -69.13M |
| Total Depreciation and Amortization | 519.00K | 477.00K | 433.00K | 396.00K | 357.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.92M | 14.34M | 12.75M | 12.73M | 12.28M |
| Change in Net Operating Assets | -729.00K | 5.21M | 4.73M | -1.00K | 6.36M |
| Cash from Operations | -69.77M | -63.72M | -62.96M | -62.32M | -50.14M |
| Capital Expenditure | -664.00K | -1.26M | -1.29M | -865.00K | -770.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -97.74M | -248.54M | -270.15M | -125.63M | -143.84M |
| Cash from Investing | -98.40M | -249.80M | -271.44M | -126.49M | -144.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 202.56M | 202.18M | 201.90M | 201.65M | 1.54M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -420.00K | -420.00K | -420.00K | -169.00K | -- |
| Cash from Financing | 202.14M | 201.76M | 201.48M | 201.48M | 1.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.96M | -111.76M | -132.92M | 12.67M | -193.21M |